

## Process for the preparation of heterologous bispecific antibodies

**Publication number:** JP9506001 (T)

**Publication date:** 1997-06-17

**Inventor(s):**

**Applicant(s):**

**Classification:**

**- international:** **C12N15/02; C07K1/22; C07K16/12; C07K16/46; C12P21/08; C12R1/91; C12N15/02; C07K1/00; C07K16/12; C07K16/46; C12P21/08; (IPC1-7): C07K16/12; C12P21/08; C07K1/22; C07K16/46; C12N15/02; C12P21/08; C12R1/91**

**- European:** C07K16/46D

**Application number:** JP19960500228T 19950516

**Priority number(s):** DE19944419399 19940603; WO1995EP01850 19950516

**Also published as:**

 JP3400457 (B2)

 DE4419399 (C1)

 EP0763128 (A1)

 EP0763128 (B1)

 AT187176 (T)

[more >>](#)

Abstract not available for JP 9506001 (T)

Abstract of corresponding document: **DE 4419399 (C1)**

The invention pertains to a method for producing heterologous bispecific antibodies. The object of the invention is a method designed to yield heterologous bispecific antibodies with a high level of purity. This is attained by producing a quadroma fused from hybridomas, one of which produces antibodies that have an affinity to the binding site of protein A and the other of which produces antibodies that have a weaker or no affinity to the binding site of protein A; by propagating and cultivating the quadromas as usual, and by eluting the bsAk in a pH range at least 0.5 units above the pH at which the antibodies with greater affinity to the binding site of protein A are still bonded.

---

Data supplied from the **esp@cenet** database — Worldwide

(19)日本国特許庁 (JP)

## (12) 公表特許公報 (A)

(11)特許出願公表番号

特表平9-506001

(43)公表日 平成9年(1997)6月17日

(51) Int.Cl. <sup>6</sup>	識別記号	序内整理番号	F I
C 12 P 21/08		9358-4B	C 12 P 21/08
C 07 K 1/22		9356-4H	C 07 K 1/22
16/46		9356-4H	16/46
C 12 N 15/02		9356-4H	16/12
// C 07 K 16/12		9162-4B	C 12 N 15/00
			C
	審査請求 有	予備審査請求 有	(全 25 頁) 最終頁に続く

(21)出願番号	特願平8-500228
(86) (22)出願日	平成7年(1995)5月16日
(85)翻訳文提出日	平成8年(1996)12月2日
(36)国際出願番号	PCT/EP95/01850
(37)国際公開番号	WO95/33844
(37)国際公開日	平成7年(1995)12月14日
(31)優先権主張番号	P 4 4 1 9 3 9 9. 8
(32)優先日	1994年6月3日
(33)優先権主張国	ドイツ(DE)
(31)指定国	EP(AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, M C, NL, PT, SE), CA, JP, US

(71)出願人	ゲーエスエフーフォルシュングスツエント ルム フュア ウムヴェルト ウント ゲ ズントハイト ゲゼルシャフト ミット ベシュレンクテル ハフツング ドイツ連邦共和国 D-85764 オーバー シュライスハイム インゴルシュテッター ラントシュトラーセ 1
(72)発明者	ホルスト リントホーファー ドイツ連邦共和国 D-80999 ミュンヘ ン トリクスルヴェーク 7
(72)発明者	シュテファン ティールフェルダー ドイツ連邦共和国 D-82229 アイヒェ ナウ ビルケンハイム 5
(74)代理人	弁理士 矢野 敏雄 (外3名)

## (54)【発明の名称】異種二重特異性抗体の製造法

## (57)【要約】

本発明は、異種二重特異性抗体の製造法に関する。本発明の課題は、高い純度での異種二重特異性抗体を製造することができるような方法を実施することである。前記課題は、1つのハイブリドーマが、蛋白質Aの結合ドメインに対する親和性を有する抗体を生産し、別のハイブリドーマは、第一の抗体と比べて、蛋白質Aの結合ドメインに対して弱い親和性を有するかまたは親和性を有していない抗体を生産するようなハイブリドーマから融合されたクアドロームの製造、該クアドロームの常法による増殖および培養並びに蛋白質Aの結合ドメインに対してより強い親和性を有する抗体がなお結合しているpHを少なくとも0.5単位上回っているpH範囲内でのbsA kの溶離によって解決される。



























## 文献

[1]

Karawajew L., Micheel B., Behrsing O., Gaestel M.  
. (1987) J. Immunol. Methods 96:265

[2]

Nitta T., Sato K., Yayita H., Okumura K., Ishii  
S. (1990) Lancet 335:368

[3]

MacLean J. A., Su Z., Guo Y., Sy M., Colvin R. B  
. Wong J. T. (1993) J. Immunol. 150:1619-1628

[4]

Brennan M., Davison P. F., Paulus H. (1985) Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1-fragments. Science 229:81

[5]

Kostelny S. A., Cole M. S., Tso J. Y. (1992) J.  
Immunol. 148 : 1547-1553

[6]

Clark M., Gilliland L., Waldmann H. (1988) Hybri

d antibodies for therapy. Monoclonal antibody therapy. Prog Allergy. Basel, Karger, vol 45:31-49

[7]

De Lau W. B. M., Heijne K., Neefjes J. J., Oosterwegel M., Rozemuller E., Bast B. J. E. G. (1991) Absence of preferential homologous H/L chain association in hybrid-hybridomas. J. Immunol. 146: 906-9 14

[8]

Link B. K., Weiner G. J. (1993) Production and characterization of bispecific IgG capable of inducing T-cell mediated lysis of malignant B cells. Blood 81:3343-3349

[9]

Ey P. L., Prowse S. J., Jenkin C. R. (1978) Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-Sephadex. Immunochimistry 15:429-436

[10]

Couderc J., Kazatchkine M. D., Ventura M., Duc H. T., Maillet F., Thobie N., Liacopoulos P. (19

85) Activation of the human classical complement pathway by a mouse monoclonal hybrid IgG1-2a monovalent anti-TNP antibody bound to TNP-conjugated cells. *J. Immunol.* 134:486-491

[11]

Kuppen P. J. K. et al. (1993) The development and purification of a bispecific antibody for lymphokine-activated killer cell targeting against the rat colon carcinoma CC531. *Cancer Immunol. Immunother.* 36:403-408

[12]

Deisenhofer J. (1981) Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from *Staphylococcus aureus* at 2.9 and 2.8 Å resolution. *Biochemistry* 20:2361-2370

[13]

Rousseaux J., Rousseaux-Prevost R. f Bazin H.. Biserre G. (1981) Tryptic cleavage of rat IgG: a comparative study between subclasses. *Immunol. Lett.* 3:93

【図 1】






Fig. 2

O.D.280




【図 3】

O.D. 280



【図4】

O.D. 280



**INTERNATIONAL SEARCH REPORT**

International Application No.  
PCT/EP 95/01850

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C12P21/08 C07K1/22 C07K16/46

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12P C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB,A,2 197 323 (NATIONAL RESEARCH DEVELOPMENT CORPORATION) 18 May 1988 see examples 2,6 see claims ----- GB,A,2 197 322 (NATIONAL RESEARCH DEVELOPMENT CORPORATION) 18 May 1988 see examples 5,9 see claims ----- -/-	1-4  1
X		

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

Date of the actual completion of the international search

25 September 1995

Date of mailing of the international search report

13 - 10 - 95

Name and mailing address of the ISA  
European Patent Office, P.B. 581 8 Patentkantoor 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Telex 31 651 epo nl  
Fax (+31-70) 340-3016

Authorized officer

Nooit, F

## INTERNATIONAL SEARCH REPORT

Intern'l Application No  
PCT/EP 95/01850

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	INTERNATIONAL JOURNAL OF CANCER, vol. 55, no. 6, 2 December 1993 GENF, DIE SCHWEIZ, pages 931-937, S. FERRINI ET AL. 'Targeting of T lymphocytes against EGF-receptor+ tumor cells by bispecific monoclonal antibodies: Requirement of CD3 molecule cross-linking for T-cell activation.' see page 932, right column, line 16 - page 933, right column, line 8 ---	1-9
A	COMPTES RENDUS DE L'ACADEMIE DES SCIENCES, vol. 310, no. 9, 26 April 1990 PARIS, pages 377-382, V. LEBEGUE ET AL. 'Production et caractérisation d'anticorps monoclonaux hybrides présentant une double isotypie IgG1/IgG3.' see "Abridged English version" ---	1-9
A	JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 79, no. 6, December 1987 BETHESDA, MD, VSA, pages 1393-1401, M. CLARK ET AL. 'T-cell killing of target cells induced by hybrid antibodies: Comparison of two bispecific monoclonal antibodies.' see the whole document ---	1-9
P,O, X	EXPERIMENTAL HEMATOLOGY, vol. 22, no. 8, 21 August 1994 - 25 August 1994 NEW YORK, NY, VSA, page 763 H. LINDHOFER ET AL. 'Rat-mouse quadromas allow augmented generation of bispecific antibodies and single step purification. First in vivo studies.' see abstract 321 ---	1-4
P,X	IMMUNOBIOLOGY, vol. 191, no. 2-3, September 1994 STUTTGART, DEUTSCHLAND, page 248 H. LINDHOFER ET AL. 'Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas detected during single step purification of bispecific antibodies on protein A.' see abstract L4 -----	1-4

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP 95/01850

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
GB-A-2197323	18-05-88	AU-B-	616870	14-11-91
		AU-A-	8156887	01-06-88
		EP-A-	0293405	07-12-88
		WO-A-	8803566	19-05-88
		JP-T-	1501201	27-04-89
-----	-----	-----	-----	-----
GB-A-2197322	18-05-88	AU-B-	616871	14-11-91
		AU-A-	8156987	01-06-88
		EP-A-	0289546	09-11-88
		WO-A-	8803565	19-05-88
		JP-T-	1501200	27-04-89
-----	-----	-----	-----	-----

